EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Shifting tides from non-targeted chemotherapy to targeted therapies and small RNA-based bio drugs: A changing paradigm in cancer therapy

Mridul Gautam, Chethana D Kumar, Pournami Ramachandran, Aviral Kumar, Indresh K Gopalsamy, Guruprasadh Swaminathan, Marco Cordani, Lekha Dinesh Kumar

European Journal of Pharmacology · 2026

DOI: 10.1016/j.ejphar.2025.178446 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Mridul Gautam und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology, CSIR- Centre for Cellular and Molecular Biology (CCMB), Hyderabad, 500007, India. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents, Molecular Targeted Therapy, RNA, Small Interfering. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 379 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Council of Scientific and Industrial Research, India, European Commission, State Agency of Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ever since its discovery in the early 20th century, chemotherapy has been the mainstream therapy for almost all cancers. Though several cycles of chemotherapy significantly reduce the proliferation and spread of the disease, they cause deleterious side effects. The adverse effects on the immune system imposed by these non-specific cytotoxic chemo drugs forced scientists to focus and give importance to boosting the immune system with a series of specific biological therapies. Stimulating or modulating the immune system to recognize and strike cancer cells (immunotherapy), combining with the application of gene knock down through RNA interference (RNAi) have spearheaded the cancer biotherapies, propelling them towards a more targeted and efficacious therapy regimen. Immunotherapy uses drugs like monoclonal antibodies, checkpoint inhibitors, and chimeric antigen receptor (CAR)-T cell therapy to enhance the immune response. These immune-based therapies can improve the specificity of cancer targeting and overcome immune evasion mechanisms employed by cancer cells. Further, soon after RNAi discovery, efforts have been made to adopt RNAi for its clinical applications in treating cancer. Different non-coding RNAs (ncRNAs) exert a distinct influence on gene expression and its regulation, offering a diversified toolkit for manipulating cellular pathways in the fight against cancer. This review article summarizes the currently used chemo drugs and their adverse effects and the shift of focus towards small RNA based bio-drugs as future cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsAntineoplastic AgentsMolecular Targeted TherapyRNA, Small InterferingHumansAnimalsImmunotherapyRNA Interference

Stichwörter der Autor:innen

Bio drugsChemotherapyClinical trialsImmunotherapyMonoclonal antibodiesRNA-InterferencencRNAs

Substanzen

Antineoplastic AgentsRNA, Small Interfering

Autor:innen und Institutionen

  • Cancer Biology, CSIR- Centre for Cellular and Molecular Biology (CCMB), Hyderabad, 500007, India.
  • Department of Surgical ICU, Christian Medical College, IDA Scudder Road, Vellore, 632004, Tamil Nadu, India.
  • Department of Biochemistry and Molecular Biology, Faculty of Biological Sciences, Complutense University of Madrid, 28040, Madrid, Spain; Instituto de Investigaciones Sanitarias San Carlos (IdISSC), 28040, Madrid, Spain…
  • Cancer Biology, CSIR- Centre for Cellular and Molecular Biology (CCMB), Hyderabad, 500007, India. Electronic address: lekha@ccmb.res.in.

Förderung

  • Council of Scientific and Industrial Research, India
  • European Commission
  • State Agency of Research

Zitieren

APA

Gautam, M., Kumar, C. D., Ramachandran, P., Kumar, A., Gopalsamy, I. K., Swaminathan, G., Cordani, M., & Dinesh Kumar, L. (2026). Shifting tides from non-targeted chemotherapy to targeted therapies and small RNA-based bio drugs: A changing paradigm in cancer therapy. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178446

Vancouver

Gautam M, Kumar CD, Ramachandran P, Kumar A, Gopalsamy IK, Swaminathan G, et al. Shifting tides from non-targeted chemotherapy to targeted therapies and small RNA-based bio drugs: A changing paradigm in cancer therapy. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2025.178446

BibTeX
@article{Gautam2026,
  author = {Gautam, Mridul and Kumar, Chethana D and Ramachandran, Pournami and Kumar, Aviral and Gopalsamy, Indresh K and Swaminathan, Guruprasadh and Cordani, Marco and Dinesh Kumar, Lekha},
  title = {Shifting tides from non-targeted chemotherapy to targeted therapies and small RNA-based bio drugs: A changing paradigm in cancer therapy},
  journal = {European Journal of Pharmacology},
  year = {2026},
  doi = {10.1016/j.ejphar.2025.178446}
}
Kostenlos starten →